Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKinsey
Moodys
Dow
Express Scripts

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

ZEVALIN Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ZEVALIN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
University of California, DavisPhase 2
Duke UniversityPhase 2

See all ZEVALIN clinical trials

Recent Litigation for ZEVALIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Biogen Idec, Inc. v. Glaxosmithkline LLC2010-03-24
IDERA PHARMACEUTICALS, INC. v. KAPPOS2010-01-29
Genentech, Inc. v. Sanofi-Aventis Deutschland GMBH2008-10-27

See all ZEVALIN litigation

Company Disclosures: US Patents for ZEVALIN

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Idec Pharmaceuticals Corporation (San Diego, CA) 2015-04-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2015-07-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial 2015-12-01 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2039-03-29 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceutical Corporation (San Diego, CA) 2019-06-04 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2021-01-27 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ZEVALIN

These patents were identified by searching patent claims

Supplementary Protection Certificates for ZEVALIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
C00669836/01 Switzerland   Start Trial FORMER OWNER: BIOGEN INC., US
CA 2004 00021 Denmark   Start Trial PRODUCT NAME: IBRITUMOMAB TIUXETAN
122009000070 Germany   Start Trial PRODUCT NAME: RITUXIMAB; NAT. REGISTRATION NO/DATE: EU/1/98/067/001-002 19980602; FIRST REGISTRATION: CH IKS 54378 01 19971127
CA 2015 00043 Denmark   Start Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
04C0018 France   Start Trial PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKinsey
Medtronic
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.